AzTrials
AzTrials

Appendicitis AcutePhase 2NCT04717193

Laparoscopically Guided Rectus Sheath Block in Pediatric Appendicitis

A Phase 2 study testing Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine and Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine in people with Appendicitis Acute, run by University of Alberta at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study will investigate the pain control effects of a rectus sheath block after laparoscopic surgery to remove the appendix. A rectus sheath block is the injection of local anesthetic (numbing agent) into the space between the muscles of the belly wall. Read more about this study

Who is it for?
Ages 8 to 17 years
Conditions the study is for
Appendicitis Acute
What is being tested?
Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine and Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
42 participants
Where
1 siteCanada
Study dates
28 May 2021to 17 Apr 2023
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Diagnosis of acute uncomplicated appendicitis
  • Age 8-17 years

Who cannot join

  • Complicated appendicitis, perforation, abscess
  • History of chronic pain condition or long-term analgesic use
  • History of bleeding condition
  • Condition preventing accurate documentation of post-operative pain scores using the FPS-R tool including severe developmental delay, psychiatric illness, or partially sighted or blindness
  • Previous open abdominal surgery
  • Presence of an abdominal prosthesis such as a gastrostomy tube or ventricular-peritoneal shunt device
  • Allergy to bupivacaine or morphine

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Stollery Children's Hospital

    Edmonton, Alberta, T6G2B7

Other trials in Canada

About this study

Official title: Laparoscopically Guided Rectus Sheath Block in Pediatric Appendicitis - a Randomized Control Trial

The study will investigate the pain control effects of a rectus sheath block after laparoscopic surgery to remove the appendix. A rectus sheath block is the injection of local anesthetic (numbing agent) into the space between the muscles of the belly wall. Children having surgery for appendicitis age 8-17 at the Stollery Children's Hospital will be eligible to participate. Patients with complicated appendicitis (perforation or abscess), chronic pain, bleeding disorders, or inability to document pain scores will be excluded from this study.

Participants will be randomly assigned to either rectus sheath block or standard local anesthetic. The standard local anesthetic group will have local anesthetic (numbing agent) injected around their surgery cut sites. The rectus sheath block group will have this standard plus the rectus sheath block with local anesthetic. Participants, parents, anesthesiologists and nursing staff will not know which group the participant has been assigned to. The surgeon will know the group.

The same pain and nausea medications will be ordered for all participants after the surgery. Pain scores will be measured using the Faces Pain Scale - Revised tool. Participants will be asked to rate their pain in the recovery room, in their hospital room at 3 and 6 hours after the surgery and again before going home. This tool has been shown to be useful for rating children's pain levels. The study will also measure the amount of pain and nausea medications that participants are given during their surgery and recovery. Participants will see their surgeon at 6 weeks after their surgery where they will be asked about any problems after being discharged home. Data will be analyzed with a linear mixed model.

Read the detailed description

Purpose:

To determine if a bilateral laparoscopically guided rectus sheath block improves pain control over conventional local anesthetic infiltration around port site incisions following laparoscopic appendectomy.

Hypothesis:

Bilateral rectus sheath block will improve post-operative pain scores following laparoscopic appendectomy for acute uncomplicated appendicitis.

Justification:

Children have significant pain after laparoscopic appendectomy and many receive post-operative opioids for analgesia. The Faces pain scale - revised (FPS-R) is a simple validated method of measuring post-operative pain in children. Ultrasound-guided bilateral rectus sheath block (RSB) has been shown to decrease pain scores in the early post-operative period following pediatric laparoscopic appendectomy and elective umbilical hernia repair.2,4 The use of image-guidance for needle placement has improved both achievement of appropriate anatomic location of the block as well as analgesia associated with the block. Under ultrasound guidance, this extra step requires additional equipment, time, and sometimes dedicated personnel to complete. The investigators propose a bilateral RSB performed intra-operatively under laparoscopic guidance may alleviate the need for these extra resources while achieving the desired analgesic effects.

The analgesic effect of the standard of care injection of local anesthesia is limited to the superficial layers of the abdominal wall. The rectus sheath block targets the nerves running within the fascia and provides a more complete block to the deep and superficial layers of the abdominal wall.

Objectives:

Primary Objective: Determine if intra-operative laparoscopic guided bilateral RSB improves self-reported post-operative pain scores at 3 hours post-operatively.

Secondary Objectives:

Determine if intra-operative laparoscopic guided bilateral RSB improves self-reported post-operative pain scores in the PACU, at 6 hours post-operatively, and prior to discharge home.

Determine if intra-operative bilateral laparoscopic guided bilateral RSB decreases intra-operative narcotic use, post-operative opioid use, and post-operative antiemetic use.

Research Methods/Procedures:

Randomization: Simple

Blinding: Single-blind. Surgeon cannot be blinded to the intervention. Anesthesiologist, participants, parents, and nursing staff in the OR, recovery room, and ward will be blinded.

Control: Standard of care infiltration of local anesthetic at incisions.

Treatment and standard care arms will run in parallel.

Standard Care: Intra-operative infiltration of 2ml of 0.25% Bupivacaine with 1:200 000 epinephrine at each port site incision.

Experimental Treatment: Bilateral RSB with up to 7ml of 0.25% Bupivacaine with 1:200 000 epinephrine plus 2ml infiltrated around each port site incision as in the standard care group. The total volume used will not exceed 20ml or 2mg/kg, whichever is lower.

Each participant will be followed in the recovery room and surgical ward and asked to report their pain level immediately after surgery, at 3 and 6 hours after surgery, and prior to discharge home. Each participant will have a scheduled follow up visit at 6 weeks with their operating surgeon where they will be asked about any complications experienced since discharge.

Participation will be voluntary. Participants will receive standard of care if they choose not to participate in the study. Informed consent will be obtained from the participant's parent or legal guardian by the operating surgeon or delegate pre-operatively. Participants will be asked to provide assent.

Plan for Data Analysis:

100 participants will be required with a target of 50 in each group. Sample size calculations were completed based on an estimated 20% effect size with consideration for a potential 10-15% dropout rate to achieve a power of 80% and alpha 5%. Effect size is estimated conservatively from data in previous studies showing an average 30% decrease in early post-operative pain scores.

Data will be analyzed in an intent to treat manner using a linear mixed model. We have undertaken an initial consultation with a WCHRI biostatistician.

Being tested
Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine, Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine
Medical subject headings
Appendicitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrineDrug

    Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.

  • Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrineProcedure or surgery

    Infiltration of local anesthetic at incision sites.

Study groups in NCT04717193
Study groupRoleWhat they receive
Rectus Sheath BlockExperimentalParticipants randomized to the experimental arm will receive a bilateral rectus sheath block which is additional to the standard of care (infiltration of 5mg (2mL) 0.25% bupivacaine with epinephrine around port site incisions). For rectus sheath block, use the formula Volume (ml) = 2mg/kg x weight (kg) divided by 2.5mg/ml - 6ml to a maximum of 14ml. Maximum total dose is 2mg/kg. Participants will be asked to rate their pain a total of 4 times for the study. Each occurrence is expected to take approximately 1-2 minutes to complete. There will be no additional follow-up required as part of the study. The 6 week follow-up visit is standard routine practice.
Receives: Drug: Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine
Local AnestheticActive comparatorParticipants in the control arm will receive the standard care which is infiltration of 5mg (2mL) of 0.25% bupivacaine with epinephrine around port site incisions. Participants will be asked to rate their pain a total of 4 times for the study. Each occurrence is expected to take approximately 1-2 minutes to complete. There will be no additional follow-up required as part of the study. The 6 week follow-up visit is standard routine practice.
Receives: Procedure: Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Self-reported pain scores at 3 hours post-operatively

    Reported with Faces Pain Scale - Revised. Scale runs from 0-10 with 0 being no pain and 10 being the worst pain they have experienced.

    Measured: 3 hours

Secondary outcomes (4)
  1. Self-reported pain scores in recovery room, at 6 hours post-operatively, and prior to discharge home

    Reported with Faces Pain Scale - Revised. Scale runs from 0-10 with 0 being no pain and 10 being the worst pain they have experienced.

    Measured: Immediately post-operatively to approximately 24 hours

  2. Intra-operative narcotic use in mg/kg morphine equivalents

    Opioid medications administered intra-operatively

    Measured: Intra-operative

  3. Post-operative narcotic use in mg/kg morphine equivalents

    Opioid medications administered post-operatively

    Measured: Approximately 24 hours

  4. Post-operative anti-emetic use mg/kg or ondansetron and dimenhydrinate

    Anti-emetic medications (ondansetron and dimenhydrinate) administered post-operatively

    Measured: Approximately 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jan 2021
  2. Study start28 May 2021
  3. Primary completion17 Apr 2023
  4. Study completion17 Apr 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
42 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04717193
Sponsor's protocol ID
RSB-001
Status last verified
Mar 2024
First submitted
13 Jan 2021
Last updated
12 Mar 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be made available to other researchers. For inquiries relating to the study protocol or other supporting information, researchers are invited to contact the study's principal investigator.

Publications

  • Dingeman RS, Barus LM, Chung HK, Clendenin DJ, Lee CS, Tracy S, Johnson VM, Dennett KV, Zurakowski D, Chen C. Ultrasonography-guided bilateral rectus sheath block vs local anesthetic infiltration after pediatric umbilical hernia repair: a prospective randomized clinical trial. JAMA Surg. 2013 Aug;148(8):707-13. doi: 10.1001/jamasurg.2013.1442.

    PubMed 23760519
  • Tomecka MJ, Bortsov AV, Miller NR, Solano N, Narron J, McNaull PP, Ricketts KJ, Lupa CM, McLean SA. Substantial postoperative pain is common among children undergoing laparoscopic appendectomy. Paediatr Anaesth. 2012 Feb;22(2):130-5. doi: 10.1111/j.1460-9592.2011.03711.x. Epub 2011 Sep 29.

    PubMed 21958060
  • Hamill JK, Liley A, Hill AG. Rectus sheath block for laparoscopic appendicectomy: a randomized clinical trial. ANZ J Surg. 2015 Dec;85(12):951-6. doi: 10.1111/ans.12950. Epub 2015 Jan 12.

    PubMed 25581711
  • Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain. 2001 Aug;93(2):173-183. doi: 10.1016/S0304-3959(01)00314-1.

    PubMed 11427329

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine and Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine in people with Appendicitis Acute, run by University of Alberta at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Self-reported pain scores at 3 hours post-operatively (time frame: 3 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04717193, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in